

When citing an abstract from the 2025 annual meeting, please use the format below.

[Authors]. [Abstract Title]. Program No. XXX.XX. 2025 Neuroscience Meeting Planner.
San Diego, CA: Society for Neuroscience, 2025. Online.

2025 Copyright by the Society for Neuroscience all rights reserved. Permission to republish any abstract or part of any abstract in any form must be obtained in writing by SfN office prior to publication.

Information is current as of October 1, 2025. See the Neuroscience 2025 Neuroscience Meeting Planner on SfN.org for the most up-to-date information.

Basic-Translational-Clinical Roundtables

BTCR01: From Traumatic Brain Injury to Post-Traumatic Epilepsy: Mechanistic Linkage Through Biomarkers, Inflammation, *In Vivo* Imaging, and Multiomics — Fletcher A. White

Location: SDCC Rm 6DE

Time: Monday, November 17, 2025, 10:30 AM - 12:00 PM

Description: The debilitating neurological consequence of traumatic brain injury (TBI), including post-traumatic epilepsy (PTE) remains without preventive therapies. Developing novel therapeutic strategies awaits better animal models and greater insight into mechanisms and biomarkers. This roundtable will host experts presenting novel mechanistic findings, biomarkers, and recently developed PTE animal models, providing a unique opportunity to engage the audience in potentially controversial topics.

Program #: BTCR01.01

Chair: F. A. White;
Indiana University, Indianapolis, Indianapolis, IN

Disclosures:

Program #: BTCR01.02

Speaker: M. Obeid;
Indiana University School of Medicine, Indianapolis, IN

Disclosures: M. Obeid: None.

Program #: BTCR01.03

Speaker: K. Wang;
Neuroscience Institute, Morehouse School of Medicine, Atlanta, GA

Disclosures: K. Wang: E. Ownership Interest (stock, stock options, royalty, receipt of intellectual property rights/patent holder, excluding diversified mutual funds); Shareholder of Gryphonbio, Shareholder of Owl therapeutics , LLC.

Program #: BTCR01.04

Speaker: E. R. Zanier;
Mario Negri Institute for Pharmacological Research IRCCS, Milano, Italy

Disclosures: E.R. Zanier: None.

Basic-Translational-Clinical Roundtables

BTCR02: Integrating Academic and Industry Contributions to Accelerate the Path From Target Biology to Patient Intervention — Fiona E. Ducotterd

Location: SDCC Rm 6DE

Time: Tuesday, November 18, 2025, 10:30 AM - 12:00 PM

Description: Patients are waiting for treatments. Translational research and drug discovery from target identification to human efficacy studies take years. By building academic innovator connections with industrial processes, we can shorten these timelines and bring benefits to patients from discoveries more rapidly. This session will discuss the areas of opportunity in working at the interface of academia and industry and opportunities to build stronger bridges across neuroscience in this area.

Program #: BTCR02.01

Chair: F. E. Ducotterd;
University College London, London, United Kingdom

Disclosures:

Program #: BTCR02.02

Speaker: C. P. MacSweeney;
Nxera Pharma UK Ltd, Cambridge, United Kingdom

Disclosures: C.P. MacSweeney: A. Employment/Salary (full or part-time); Nxera Pharma UK Ltd.

Program #: BTCR02.03

Speaker: F. Murray;
Pheno Therapeutics, Edinburgh, United Kingdom

Disclosures: F. Murray: A. Employment/Salary (full or part-time); Pheno Therapeutics.

Program #: BTCR02.04

Speaker: J. Ray;
Belfer Neurodegeneration Consortium, MD Anderson Cancer Center, Houston, TX

Disclosures: J. Ray: C. Other Research Support (receipt of drugs, supplies, equipment or other in-kind support); Balchem, Inc.. F. Consulting Fees (e.g., advisory boards); Cerevance, Keystone Bio, Orbimed, Neurovanda, Reservoir Neuroscience.

Basic-Translational-Clinical Roundtables

BTCR03: Roadmap for Direct Translation of Optogenetics Into Human Therapies — Christian Lüscher

Location: SDCC Rm 6A

Time: Wednesday, November 19, 2025, 10:30 AM - 12:00 PM

Description: Brain diseases impose a growing burden worldwide, largely due to limited understanding of their pathophysiology. Optogenetics has transformed neural circuit research, but it has not yet led to novel brain disease treatments. The speakers will list the challenges for the direct translation of optogenetics in humans and consider how it can refine currently existing circuit therapies. They will discuss the clinical opportunities, technical challenges, and ethical issues linked with such circuit interventions.

Program #: BTCR03.01

Support: ERC F-addict
SNF Support
NIH Support
ISF Support

Chair: C. Lüscher;
University of Geneva, Geneva, Switzerland

Disclosures: C. Lüscher: A. Employment/Salary (full or part-time);; University of Geneva and University Hospital Geneva. E. Ownership Interest (stock, stock options, royalty, receipt of intellectual property rights/patent holder, excluding diversified mutual funds); Stockoptions for Stalicia SA.

Program #: BTCR03.02

Speaker: O. Yizhar;
Weizmann Institute of Science, Rehovot, Israel

Disclosures: O. Yizhar: A. Employment/Salary (full or part-time);; Weizmann Institute. E. Ownership Interest (stock, stock options, royalty, receipt of intellectual property rights/patent holder, excluding diversified mutual funds); Co-founder and scientific consultant to Modulight.bio.

Program #: BTCR03.03

Speaker: K. Deisseroth;
Stanford University, Stanford, CA

Disclosures: K. Deisseroth: A. Employment/Salary (full or part-time);; Stanford University. E. Ownership Interest (stock, stock options, royalty, receipt of intellectual property rights/patent holder, excluding diversified mutual funds); K.D. is a founder and scientific advisor for Maplight Therapeutics and Stellaromics, and a scientific advisor to RedTree LLC and Modulight.. F.

Consulting Fees (e.g., advisory boards); K.D. and Michelle Monje-Deisseroth hold equity in all 4 entities..

Program #: BTCR03.04

Speaker: N. A. Farahany;
Duke University, Durham, NC

Disclosures: N.A. Farahany: A. Employment/Salary (full or part-time);; Duke University. D. Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus); Lavin Agency Speakers' Bureau. F. Consulting Fees (e.g., advisory boards); Advisory board of OpenBCI.

Dual Perspectives

DUP01: What Is in a Name?: Define the Boundaries of Neuronal Cell Types — Victoria Abraira

Location: SDCC Rm 6DE

Time: Sunday, November 16, 2025, 10:30 AM - 12:00 PM

Description: A question that has plagued neuroscientists since Cajal is: What defines a cell type? Large-scale efforts have yielded consensus brain-cell taxonomies, but multiple schemes are used to classify somatosensory neurons. In this session, experts will weigh pros and cons of taxonomies rooted in functional and molecular properties. The panel aims to spur discussion and community-driven efforts to develop a unified taxonomic framework that spans biological scales, states, and species.

Moderator:

***V. ABRAIRA;**

Rutgers, The State University of New Jersey, warren, NJ

Disclosures:

Speaker:

T. J. Price;

University of Texas at Dallas, Dallas, TX

Disclosures: T.J. Price: None.

Speaker:

A. T. Chesler;

NIH/NCCIH, Bethesda, MD

Disclosures: A.T. Chesler: None.

Storytelling

STR01: Visible and Invisible Disabilities: Unique Experiences Require Tailored Approaches — Jennifer C. Tudor

Location: SDCC Rm 6DE

Time: Monday, November 17, 2025, 1:30 PM - 3:00 PM

Description: Individuals with disabilities are not a monolithic group; there are varying modalities and degrees of disability that lead to unique formative experiences. This brings a host of challenges with regard to training and mentorship, but also opportunities for growth for all in the academic environment. In this session, presenters will share their stories and experiences with disabilities to highlight lessons learned from these lived experiences.

Program #: STR01.01

Chair: J. C. Tudor;

Saint Joseph's University, Philadelphia, PA

Disclosures: J.C. Tudor, None.

Using the biopsychosocial model of disability to inform mentorship practices

Program #: STR01.02

Speaker: J. C. Tudor;

Saint Joseph's University, Philadelphia, PA

Disclosures: J.C. Tudor: None.

Program #: STR01.03

Disability and accommodation: individualizing support systems

Speaker: Z. Simon;

University of Florida, Gainesville, FL

Disclosures: Z. Simon: None.

Program #: STR01.04

Understanding the intersection of disability and imposter syndrome

Speaker: I. K. Succi;

Zuckerman Institute at Columbia University, New York, NY

Disclosures: I.K. Succi: None.

Program #: STR01.05

Maximizing the power of neurodiversity in higher education

Speaker: L. K. Fung;

Stanford University, Palo Alto, CA

Disclosures: L.K. Fung: F. Consulting Fees (e.g., advisory boards); Sage Therapeutics.